Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.40 |
| ▸ | SMO | Q99835 | 1/20 | 0.39 |
| ▸ | RXRA | P19793 | 1/20 | 0.39 |
| ▸ | CKS1B | P61024 | 5/20 | 0.39 |
| ▸ | SKP1 | P63208 | 5/20 | 0.39 |
| ▸ | SKP2 | Q13309 | 5/20 | 0.39 |
| ▸ | PDE10A | Q9Y233 | 4/20 | 0.39 |
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27253445 | 0.90 | HRH3 (0.52) | HRH3ACKR3SMOPDE10AKDM1A | |
| SCHEMBL30432036 | 0.83 | SMO (0.53) | HRH3SMO | |
| SCHEMBL24379245 | 0.83 | SMO (0.53) | HRH3SMO | |
| SCHEMBL25933688 | 0.82 | MAPT (0.50) | HRH3ACKR3SMO | |
| SCHEMBL26712643 | 0.82 | TTR (0.40) | HRH3ACKR3SMOCKS1BSKP1 | |
| SCHEMBL26712640 | 0.82 | TTR (0.40) | HRH3ACKR3SMOCKS1BSKP1 | |
| SCHEMBL26712523 | 0.82 | TTR (0.40) | HRH3ACKR3SMOCKS1BSKP1 | |
| SCHEMBL4036526 | 0.80 | HRH3 (0.54) | HRH3SMO | |
| SCHEMBL4032468 | 0.80 | HRH3 (0.42) | HRH3SMO | |
| SCHEMBL24420935 | 0.79 | KDM4E (0.43) | HRH3PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260053932-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS INC (US) | 2026-02-26 | — | — | US | disclosed |
| US-12419960-B2 | Compounds and methods for the targeted degradation of androgen receptor and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2025-09-23 | — | — | US | disclosed |
| US-20250205344-A1 | 2,4-DIOXOTETRAHYDROPYRIMIDINYL DERATIVES AS DEGRONS IN PROTACS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2025-06-26 | — | — | US | disclosed |
| EP-4509184-A2 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | Arvinas Operations, Inc. (US) | 2025-02-19 | — | — | EP | disclosed |
| EP-4499628-A1 | 2,4-DIOXOTETRAHYDROPYRIMIDINYL DERIVATIVES AS DEGRONS IN PROTACS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2025-02-05 | — | — | EP | disclosed |
| US-20250034096-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS, INC. | 2025-01-30 | — | — | US | disclosed |
| EP-3526202-B1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS INC (US) | 2025-01-08 | — | — | EP | disclosed |
| US-12077509-B2 | Compounds and methods for the targeted degradation of androgen receptor | ARVINAS OPERATIONS, INC. (US) | 2024-09-03 | — | — | US | disclosed |
| US-11964945-B2 | Compounds and methods for the targeted degradation of androgen receptor | ARVINAS OPERATIONS, INC. (US) | 2024-04-23 | — | — | US | disclosed |
| US-11952347-B2 | Compounds and methods for the targeted degradation of androgen receptor | ARVINAS OPERATIONS, INC. (US) | 2024-04-09 | — | — | US | disclosed |
| US-10844021-B2 | Compounds and methods for the targeted degradation of androgen receptor | ARVINAS OPERATIONS, INC. (US) | 2020-11-24 | — | — | US | disclosed |
| US-10844021-B2 | Compounds and methods for the targeted degradation of androgen receptor | ARVINAS OPERATIONS, INC. (US) | 2020-11-24 | — | — | US | disclosed |
| CN-111892577-A | Compounds and methods for targeted degradation of androgen receptor | 阿尔维纳斯运营股份有限公司 | 2020-11-06 | — | — | CN | disclosed |
| EP-3660004-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | Arvinas Operations, Inc. (US) | 2020-06-03 | — | — | EP | disclosed |
| EP-3660004-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | Arvinas Operations, Inc. (US) | 2020-06-03 | — | — | EP | disclosed |
| US-20200095205-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS, INC. | 2020-03-26 | — | — | US | disclosed |
| US-10584101-B2 | Compounds and methods for the targeted degradation of androgen receptor | Arvinas, Inc. (US) | 2020-03-10 | — | — | US | disclosed |
| WO-2018071606-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | Arvinas, Inc. (US) | 2018-04-19 | — | — | WO | disclosed |
| US-20180099940-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS, INC. | 2018-04-12 | — | — | US | disclosed |
| US-20180099940-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS, INC. | 2018-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12419960-B2 | Compounds and methods for the targeted degradation of androgen receptor and associated methods of use | AR, ADRM1, CRBN | HRH3 3521/4885ACKR3 3955/4885SMO 493/4885 |
| US-20180099940-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | AR, ADRM1, CRBN | HRH3 3553/4885ACKR3 4012/4885SMO 412/4885 |
| US-10844021-B2 | Compounds and methods for the targeted degradation of androgen receptor | AR, ADRM1, CRBN | HRH3 3553/4885ACKR3 4012/4885SMO 412/4885 |
| US-11964945-B2 | Compounds and methods for the targeted degradation of androgen receptor | AR, ADRM1, CRBN | HRH3 3553/4885ACKR3 4012/4885SMO 412/4885 |
| US-11952347-B2 | Compounds and methods for the targeted degradation of androgen receptor | AR, ADRM1, CRBN | HRH3 3537/4885ACKR3 3958/4885SMO 409/4885 |
| US-12077509-B2 | Compounds and methods for the targeted degradation of androgen receptor | AR, ADRM1, CRBN | HRH3 3537/4885ACKR3 3958/4885SMO 409/4885 |
| US-20250034096-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | AR, ADRM1, CRBN | HRH3 3537/4885ACKR3 3958/4885SMO 409/4885 |
| US-20250205344-A1 | 2,4-DIOXOTETRAHYDROPYRIMIDINYL DERATIVES AS DEGRONS IN PROTACS | CRBN, AR, GNRHR | HRH3 1904/4885ACKR3 1592/4885SMO 131/4885 |
| US-20200095205-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | AR, ADRM1, CRBN | HRH3 3553/4885ACKR3 4012/4885SMO 412/4885 |
| US-10584101-B2 | Compounds and methods for the targeted degradation of androgen receptor | AR, ADRM1, CRBN | HRH3 3553/4885ACKR3 4012/4885SMO 412/4885 |
| US-20260053932-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR AND ASSOCIATED METHODS OF USE | ADRM1, AR, CRBN | HRH3 1753/4885ACKR3 2512/4885SMO 1390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.